DrugPatentWatch Database Preview
Doxazosin mesylate - Generic Drug Details
What are the generic sources for doxazosin mesylate and what is the scope of freedom to operate?
Doxazosin mesylate
is the generic ingredient in three branded drugs marketed by Pfizer, Accord Hlthcare, Actavis Elizabeth, Ani Pharms Inc, Apotex, Dava Pharms Inc, Genpharm, Heritage Pharma, Ivax Sub Teva Pharms, Mylan, Nesher Pharms, Pliva, Teva, Upsher Smith Labs, Watson Labs Inc, Yaopharma Co Ltd, and Zydus Pharms, and is included in nineteen NDAs. Additional information is available in the individual branded drug profile pages.There are fourteen drug master file entries for doxazosin mesylate. Thirty-one suppliers are listed for this compound.
Summary for doxazosin mesylate
| US Patents: | 0 |
| Tradenames: | 3 |
| Applicants: | 17 |
| NDAs: | 19 |
| Drug Master File Entries: | 14 |
| Suppliers / Packagers: | 31 |
| Bulk Api Vendors: | 82 |
| Clinical Trials: | 2 |
| Patent Applications: | 2,729 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price trends for doxazosin mesylate |
| Drug Sales Revenues: | Drug sales revenues for doxazosin mesylate |
| DailyMed Link: | doxazosin mesylate at DailyMed |
Recent Clinical Trials for doxazosin mesylate
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Pfizer | N/A |
| University of Minnesota - Clinical and Translational Science Institute | Phase 2 |
| National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 |
Pharmacology for doxazosin mesylate
| Drug Class | alpha-Adrenergic Blocker |
| Mechanism of Action | Adrenergic alpha-Antagonists |
Medical Subject Heading (MeSH) Categories for doxazosin mesylate
Synonyms for doxazosin mesylate
| (4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl)(2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methanone methanesulfonate |
| [1,4]dioxin-2-yl)methanone methanesulfonate |
| [4-(4-amino-6,7-dimethoxy-quinazolin-2-yl)piperazin-1-yl]-(2,3-dihydro-1,4-benzodioxin-3-yl)methanone; methanesulfonic acid |
| [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(2,3-dihydro-1,4-benzodioxin-2-yl)methanone; methanesulfonic acid |
| [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(2,3-dihydro-1,4-benzodioxin-3-yl)methanone; methanesulfonic acid |
| [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(2,3-dihydro-1,4-benzodioxin-3-yl)methanone;methanesulfonic acid |
| [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(2,3-dihydro-1,4-benzodioxin-3-yl)methanonemethanesulfonic acid |
| 1-(4-AMINO-6,7-DIMETHOXY-2-QUINAZOLINYL)-4-(1,4-BENZODIOXAN-2-YLCARBONYL) PIPERAZINE METHANESULFONATE |
| 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(1,4-benzodioxan-2-ylcarbonyl)piperazine monomethanesulfonate |
| 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(1,4-benzoldioxan-2-ylcarbonyl)piperazine methanesulfonate |
| 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-[(1,4-benzodioxan-2-yl)carbonyl]piperazine Methanesulfonate |
| 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-[4-(1,4-benzodioxan-2-yl)carpiperazin-1-yl)]-6,7-dimethoxyquinazoline mesylate |
| 2-[4-(2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl)piperazin-1-yl]-6,7-dimethoxyquinazolin-4-amine; methanesulfonic acid |
| 2-[4-(2,3-dihydro-1,4-benzodioxine-2-carbonyl)piperazin-1-yl]-6,7-dimethoxyquinazolin-4-amine mesylate |
| 2-[4-(2,3-dihydro-1,4-benzodioxine-2-carbonyl)piperazin-1-yl]-6,7-dimethoxyquinazolin-4-amine; methanesulfonic acid |
| 4-Amino-2-[4-(1,4-benzodioxan-2-carbonyl)piperazin-1-yl]-6,7-dimethoxyquinazoline methanesulfonate |
| 74191-85-8 (Parent) |
| 77883-43-3 |
| 91D858 |
| AB0008587 |
| AB2000045 |
| AC-6848 |
| AC1L1Y5G |
| AC1Q4GSV |
| AC1Q4GT3 |
| AKOS015895371 |
| Alfadil |
| AN-9627 |
| ANW-42738 |
| BCP12163 |
| Benur |
| C23H25N5O5.CH4O3S |
| C24H29N5O8S |
| Cardenalin |
| Cardoral |
| Cardoxan |
| Cardular |
| Cardular PP |
| Cardular Uro |
| Cardura |
| Cardura (TN) |
| Cardura XL |
| Cardura;Carduran;Cardura XL |
| Carduran |
| Carduran Neo |
| CAS-77883-43-3 |
| CCG-213583 |
| CHEBI:4709 |
| CHEMBL1200561 |
| CPD000058441 |
| CS-1830 |
| CTK7B4527 |
| D 9815 |
| D00608 |
| D4126 |
| Dedralen |
| Diblocin |
| Diblocin PP |
| Diblocin Uro |
| Doksura |
| Dosin |
| Doxaben |
| Doxazocine |
| Doxazomerck |
| Doxazosin (mesylate) |
| Doxazosin AZU |
| Doxazosin mesilate |
| Doxazosin mesilate (JP17) |
| Doxazosin mesilate, European Pharmacopoeia (EP) Reference Standard |
| Doxazosin mesylate (USAN) |
| Doxazosin mesylate [USAN:USP] |
| Doxazosin mesylate [USAN] |
| doxazosin mesylate salt |
| Doxazosin mesylate, >=97% (HPLC), powder |
| Doxazosin mesylate, United States Pharmacopeia (USP) Reference Standard |
| Doxazosin Mesylate,(S) |
| Doxazosinmesylate |
| Doxolbran |
| DSSTox_CID_25598 |
| DSSTox_GSID_45598 |
| DSSTox_RID_80991 |
| DTXSID5045598 |
| Duracin |
| EN300-53021 |
| EU-0100474 |
| FT-0625592 |
| HMS1570L17 |
| HMS2093J14 |
| HMS2097L17 |
| HMS2230L18 |
| HMS3261O10 |
| HMS3372C03 |
| HMS3654J15 |
| HMS3714L17 |
| HSDB 7082 |
| HY-B0098A |
| I06-0611 |
| J10294 |
| Kaltensif |
| KS-1052 |
| LP00474 |
| LS-110229 |
| MFCD00216023 |
| MLS000028455 |
| MLS000120399 |
| MLS001148153 |
| MLS002222292 |
| MLS006011977 |
| MolPort-003-983-427 |
| NCGC00016146-02 |
| NCGC00017136-01 |
| NCGC00018158-09 |
| NCGC00093884-01 |
| NCGC00261159-01 |
| NE52844 |
| Normathen |
| NSC-759284 |
| NSC759284 |
| Opera_ID_1881 |
| Pharmakon1600-01505976 |
| piperazin-1-yl)(2,3-dihydrobenzo[b] |
| Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-((2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl)-, monomethanesulfonate |
| Prestwick_1026 |
| Progandol |
| Prostadilat |
| PubChem2385 |
| RW2756 |
| s1324 |
| SAM002589903 |
| SCHEMBL42621 |
| SMR000058441 |
| SR-01000003045 |
| SR-01000003045-2 |
| SR-01000003045-4 |
| SR-01000003045-8 |
| Supressin |
| SW197099-3 |
| Tensiobas |
| TL8005338 |
| Tonocardin |
| Tox21_110796 |
| Tox21_110796_1 |
| Tox21_500474 |
| UK 33,274-27 |
| UK-33,274-27 |
| UK-33274 |
| UK-33274-27 |
| UK-3327427 |
| VJECBOKJABCYMF-UHFFFAOYSA-N |
| Z1259084903 |
Paragraph IV (Patent) Challenges for DOXAZOSIN MESYLATE
| Tradename | Dosage | Ingredient | NDA | Submissiondate |
|---|---|---|---|---|
| CARDURA | TABLET;ORAL | doxazosin mesylate | 019668 |
US Patents and Regulatory Information for doxazosin mesylate
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Accord Hlthcare | DOXAZOSIN MESYLATE | doxazosin mesylate | TABLET;ORAL | 202824-003 | Jun 11, 2014 | AB | RX | No | No | Start Trial | Start Trial | Start Trial | |||
| Nesher Pharms | DOXAZOSIN MESYLATE | doxazosin mesylate | TABLET;ORAL | 075609-004 | Oct 18, 2000 | DISCN | No | No | Start Trial | Start Trial | Start Trial | ||||
| Pliva | DOXAZOSIN MESYLATE | doxazosin mesylate | TABLET;ORAL | 075750-004 | Jun 8, 2001 | AB | RX | No | No | Start Trial | Start Trial | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for doxazosin mesylate
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Pfizer | CARDURA XL | doxazosin mesylate | TABLET, EXTENDED RELEASE;ORAL | 021269-002 | Feb 22, 2005 | Start Trial | Start Trial |
| Pfizer | CARDURA | doxazosin mesylate | TABLET;ORAL | 019668-003 | Nov 2, 1990 | Start Trial | Start Trial |
| Pfizer | CARDURA | doxazosin mesylate | TABLET;ORAL | 019668-002 | Nov 2, 1990 | Start Trial | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Copyright 2002-2019 thinkBiotech LLC
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2019 - 2020
NCE-1 Patent Challenge Dates 2019 - 2020
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2019 - 2020
NCE-1 Patent Challenge Dates 2019 - 2020
Preferred Citation:
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2019, www.DrugPatentWatch.com.